Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.



Status:Completed
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 65
Updated:1/14/2018
Start Date:June 8, 2012
End Date:July 13, 2015

Use our guide to learn which trials are right for you!

A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)

A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to
fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have
only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) .
Patients will be able to switch to different treatment for safety, efficacy, tolerability or
convenience during the study.

Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on
treatment. Secondary objectives are to compare reasons for discontinuation, adverse events,
cognitive impairment, medication satisfaction and change in brain volume measured by MRI.

852 Patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved
first line DMTs. Patients must be either treatment naive or have received treatment with only
one class of treatment (interferon beta preparation or glatiramer acetate) . Patients
previously treated with DMT and randomized to the DMT arm may not remain on the same
treatment for the study and will have to switch to a different class (i.e., previously
treated with glatiramer acetate will switch to interferon beta preparaption, previously
treated with interferon beta preparation will swtich to glatiramer acetate).

Entry criteria at screening include but are not limited to, age 18-65, diagnosis with RRMS,
EDSS < or equal to 6, not pregnant or planning pregnancy and women of childbearing potential
willing to use contraception throughout the study.

Exclusion criteria include but are not limited to - prior exposure to fingolimod, history of
malignancy within 5 years, other than RRMS types of MS, other diseases of the immune system,
active macular edema, systemic bacterial, viral or fungal infections, patients without
vaccine against varicella zoster, receipt of live or attentuated vaccines within a month of
screening, history of various cardiac conditions, presence of certain ECG abnormalities,
resting heart rate < 45 bpm, symptomatic bradycardia, recurrent syncope, severe untreated
sleep apnea, severe pulmonary conditions, various hepatic conditions, certain neurologic
disorders, pregnancy.

Patients may switch treatment before 3 months for safety reasons only, after 3 months for
safety, efficacy, tolerability or convenience. Treatment switch during the study may be to
any of study approved treatments irrespective of prior treatment.

Patients randomized to fingolimod will need to have 6 hours of observation for signs and
symptoms of bradycardia following administration of the first dose. Extended observation or
overnight observation may be necessary under certain circumstances. Primary objective is to
evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary
objectives are to compare reasons for discontinuation, adverse events, cognitive impairment,
medication satisfaction and change in brain volume measured by MRI. Exploratory objectives
include annualized relapse rate, OCT, MRI evaluations, biomarkers and patient reported
outcome measures.

Inclusion Criteria:

1. written informed consent must be obtained prior to any assessment being performed.

2. Male and female patients aged 18-65 years inclusive.

3. Patients diagnosed with relapsing remitting MS, defined by the 2010 revised McDonald
criteria (Pollman et al, 2011) (Appendix 1).

4. EDSS score of less than or equal to 6.

5. Patients naive to treatment or who have been treated with no more than one class of
DMT previously (interferon β preparation or glatiramer acetate), and who, per
investigator judgment, may benefit from a change of treatment class.

6. Patients who have been treated with DMF for less than 2 months total exposure and who
have a normal lymphocyte count at screening.

7. Women of childbearing potential must have a negative urine and serum β-human chorionic
gonadotropin (β-hCG) pregnancy test at screening and at baseline.

8. Before entry women must be:

- Post menopausal for at least 1 year, or

- Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
ligation or otherwise incapable of pregnancy, or

- Practicing a highly effective method of birth control if sexually active,
including hormonal prescription oral contraceptives, contraceptive injections,
contraceptive patch, intrauterine device, double barrier method (e.g., condoms,
diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner
sterilization consistent with local regulations regarding use of birth control
methods for patients participating in clinical trials, for the duration of their
participation in the study, or

- Not heterosexually active (patients who are not heterosexually active at
screening must agree to utilize a highly effective method of birth control if
they become heterosexually active during their participation in the study) 4.2
Exclusion criteria

1. Use of other investigational drugs within 30 days of screening.

2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical
classes.

3. Prior exposure to fingolimod or any other S1P receptor modulating compounds.

4. History or presence of malignancy of any organ system (other than successfully treated
basal or squamous cell carcinoma of the skin or stage 0 carcinoma of the cervix),
treated or untreated, within the past 5 years, regardless of whether there is evidence
of local recurrence or metastases.

5. Patients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Primary
Progressive MS (PPMS).

6. Patients with a history of chronic disease of the immune system other than MS or a
known immunodeficiency syndrome.

7. Patients who have been treated with:

• Natalizumab, mitoxantrone, cladribine, rituximab, alemtuzumab, ofatumumab,
ocrelizumab at any time before randomization

• Immunoglobulins, or pulse of corticosteroids with more than 6 months cumulative
exposure

• Immunosuppressive/chemotherapeutic medications (e.g., methotrexate, azathioprine,
cyclophosphamide, cellcept, Cytoxan, IVIG) with more than 6 months of cumulative
exposure and within 6 months prior to randomization

• Corticosteroids or adrenocorticotropic hormones in the past 30 days before
randomization. Patients that require corticosteroids for a relapse during the
screening period may be rescreened 30 days after the last dose.

8. History of treatment with both classes of approved first line DMT (interferon β
preparation and glatiramer acetate) or DMF exposure of 2 months or longer.

9. Patients with uncontrolled diabetes mellitus (HbA1c > 7%).

10. Diagnosis of macular edema during the screening phase. Patients with a history of
macular edema will be allowed to enter the study provided that they do not have
macular edema at the screening visit.

11. Patients with active systemic bacterial, viral or fungal infections, or known to have
AIDS, Hepatitis B, Hepatitis C infection or positive HIV antibody, Hepatitis B surface
antigen or Hepatitis C antibody tests.

12. Patients without history of chickenpox or without vaccination against varicella-zoster
virus at screening (patients may be vaccinated and rescreened one month or longer
after vaccination).

13. Patients who have received any live or live attenuated vaccines (including for
varicella-zoster or measles) within 1 month prior to baseline.

14. Patients with any medically unstable condition as assessed by the investigator.

15. Patients with a history of the following cardiovascular conditions:

• Cardiac arrest.

• myocardial infarction, unstable angina, stroke, transient ischemic attack,
decompensated heart failure requiring hospitalization, or Class III/IV heart failure
(Appendix 3).

• Congestive heart failure.

• Hypertension that is not controlled with prescribed medications. These patients may
be rescreened if blood pressure is stabilized with treatment.

• Cerebrovascular disease.

• History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick
sinus syndrome, unless patient has a pacemaker.

• Patients at higher risk of symptomatic bradycardia or heart block because of a
coexisting medical condition or certain concomitant medications.

• Patients randomized to the fingolimod arm with prolonged QTc interval at screening
(corrected QT interval > 450 ms in males and > 470 ms in females); for patients
randomized to the fingolimod treatment arm before dosing (baseline) or during the
6-hour observation period; and those patients at additional risk for QT prolongation
(e.g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on a concomitant
therapy with QT prolonging drugs with a known risk of Torsades de pointes (e.g.,
citalopram, chlorpromazine, haloperidol, methadone, erythromycin).

- Patients receiving class Ia or Class III antiarrhythmic drugs (Appendix 6)

- Patients receiving concurrent therapy with drugs that slow the heart rate or
atrioventricular conduction (e.g., beta blockers, digoxin, or heart-rate slowing
calcium channel blockers such as diltiazem, verapamil or digoxin). The
possibility to switch to drugs that do not slow the heart rate or
atrioventricular conduction should be evaluated by the physician prescribing
these drugs before initiating fingolimod treatment.

- History of sick sinus syndrome or sinoatrial heart block.

- Resting heart rate of < 45 bpm or symptomatic bradycardia

- Recurrent syncope

- Severe untreated sleep apnea

16. Patients with severe pulmonary conditions (including severe respiratory disease,
pulmonary fibrosis, active tuberculosis, severe or poorly controlled asthma).

17. Patients with any of the following hepatic conditions:

• Chronic liver or biliary disease

- Total bilirubin greater than upper limit of normal (ULN) at screening unless in
the context of Gilbert's syndrome

- Conjugated bilirubin greater than the ULN at screening

- AST (SGOT), ALT (SGPT) greater than 3 times ULN at screening

- Alkaline phosphatase (AP) greater than 1.5 times the ULN at screening

18. Serum creatinine greater than 2.0 mg/dL (176.5 µmol/L) at screening.

19. Patients with the following neurological/psychiatric disorders:

- History of substance abuse (drug or alcohol) in the past five years as determined
by the investigator

- Progressive neurological disorder other than MS which may affect study
participation as determined by the investigator

- Any serious psychiatric condition that may interfere with the patient's ability
to cooperate and comply with the study procedures as determined by the
investigator

20. Women who are pregnant or nursing (lactating) or planning to become pregnant.

21. Any condition that in the opinion of the investigator, would compromise the well-being
of the patient or the conduct of the study, or prevent the patient from meeting or
performing study requirements.

22. Pre-planned surgery or medical procedure that would interfere with the conduct of the
study.

23. Employee of the sponsor, investigator or study center, with direct involvement in the
proposed study or other studies under the direction of that investigator or study
center, as well as family members of the employees or the investigator.
We found this trial at
149
sites
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Akron, Ohio 44308
?
mi
from
Akron, OH
Click here to add this to my saved trials
Akron, Ohio 44308
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albany, New York 12208
?
mi
from
Albany, NY
Click here to add this to my saved trials
Albany, New York 12208
?
mi
from
Albany, NY
Click here to add this to my saved trials
Albuquerque, New Mexico 87108
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Alexandria, Louisiana 71301
?
mi
from
Alexandria, LA
Click here to add this to my saved trials
Alexandria, Virginia 22310
?
mi
from
Alexandria, VA
Click here to add this to my saved trials
Amherst, New York 14226
?
mi
from
Amherst, NY
Click here to add this to my saved trials
Anderson, Indiana 46016
?
mi
from
Anderson, IN
Click here to add this to my saved trials
Annapolis, Maryland 21401
?
mi
from
Annapolis, MD
Click here to add this to my saved trials
Asheville, North Carolina 28803
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28803
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlantis, Florida 33462
?
mi
from
Atlantis, FL
Click here to add this to my saved trials
Basalt, Colorado 81621
?
mi
from
Basalt, CO
Click here to add this to my saved trials
Baton Rouge, Louisiana 70808
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Bellevue, Ohio 44811
?
mi
from
Bellevue, OH
Click here to add this to my saved trials
Bothell, Washington 98011
?
mi
from
Bothell, WA
Click here to add this to my saved trials
Boulder, Colorado 80304
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Bradenton, Florida 32405
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Bronx, New York 10461
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Canton, Ohio 44718
?
mi
from
Canton, OH
Click here to add this to my saved trials
Charlotte, North Carolina 28277
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28277
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28277
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Cincinnati, Ohio 45229
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Colleyville, Texas 76034
?
mi
from
Colleyville, TX
Click here to add this to my saved trials
Columbus, Georgia 31904
?
mi
from
Columbus, GA
Click here to add this to my saved trials
Columbus, Georgia 31904
?
mi
from
Columbus, GA
Click here to add this to my saved trials
Columbus, Ohio 43205
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Cordova, Tennessee 38018
?
mi
from
Cordova, TN
Click here to add this to my saved trials
Cordova, Tennessee 38018
?
mi
from
Cordova, TN
Click here to add this to my saved trials
Cranston, Rhode Island 02920
?
mi
from
Cranston, RI
Click here to add this to my saved trials
Cullman, Alabama 35058
?
mi
from
Cullman, AL
Click here to add this to my saved trials
Dayton, Ohio 45402
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Decatur, Georgia 30030
?
mi
from
Decatur, GA
Click here to add this to my saved trials
Delray Beach, Florida 33445
?
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Denver, Colorado 80262
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80262
?
mi
from
Denver, CO
Click here to add this to my saved trials
Des Moines, Iowa 50314
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Dover, Delaware 19901
?
mi
from
Dover, DE
Click here to add this to my saved trials
Eugene, Oregon 97401
?
mi
from
Eugene, OR
Click here to add this to my saved trials
Fairfield, Connecticut 06824
?
mi
from
Fairfield, CT
Click here to add this to my saved trials
Flemington, New Jersey 08822
?
mi
from
Flemington, NJ
Click here to add this to my saved trials
Flossmoor, Illinois 60422
?
mi
from
Flossmoor, IL
Click here to add this to my saved trials
Fort Collins, Colorado 90728
?
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Fort Collins, Colorado 90728
?
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Fullerton, California 92835
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
Fulton, Maryland 20759
?
mi
from
Fulton, MD
Click here to add this to my saved trials
Grand Forks, North Dakota 58201
?
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Greensboro, North Carolina 27401
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Greensburg, Pennsylvania 15601
?
mi
from
Greensburg, PA
Click here to add this to my saved trials
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Guaynabo, 00968
?
mi
from
Guaynabo,
Click here to add this to my saved trials
Hawesville, Kentucky 42384
?
mi
from
Hawesville, KY
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Hollywood, Florida 33021
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indian Land, South Carolina 29707
?
mi
from
Indian Land, SC
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kalamazoo, Michigan 49048
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Kingston, New York 12401
?
mi
from
Kingston, NY
Click here to add this to my saved trials
Knoxville, Tennessee 37934
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Knoxville, Tennessee 37934
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Las Vegas, Nevada 89135
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89135
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89135
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89135
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Latham, New York 12110
?
mi
from
Latham, NY
Click here to add this to my saved trials
Lexington, Kentucky 40509
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Lubbock, Texas 79410
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Madisonville, Kentucky 42431
?
mi
from
Madisonville, KY
Click here to add this to my saved trials
Morgantown, West Virginia 26506
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Morgantown, West Virginia 26506
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Nashville, Tennessee 37205
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Neenah, Wisconsin 54956
?
mi
from
Neenah, WI
Click here to add this to my saved trials
New Bedford, Massachusetts 02740
?
mi
from
New Bedford, MA
Click here to add this to my saved trials
New London, Connecticut 06320
?
mi
from
New London, CT
Click here to add this to my saved trials
New Orleans, Louisiana 70115
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
230 Park Avenue, 21st Floor
New York, New York 10169
1-888-669-6682)
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
New York, NY
Click here to add this to my saved trials
230 Park Avenue, 21st Floor
New York, New York 10169
1-888-669-6682)
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
New York, NY
Click here to add this to my saved trials
230 Park Avenue, 21st Floor
New York, New York 10169
1-888-669-6682)
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
New York, NY
Click here to add this to my saved trials
Nixa, Missouri 65714
?
mi
from
Nixa, MO
Click here to add this to my saved trials
Norfolk, Virginia 23507
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Norfolk, Virginia 23507
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
North Dartmouth, Massachusetts 02747
?
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
North Kansas City, Missouri 64116
?
mi
from
North Kansas City, MO
Click here to add this to my saved trials
North Palm Beach, Florida 33408
?
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
North Richland Hills, Texas 76180
?
mi
from
North Richland Hills, TX
Click here to add this to my saved trials
Northbrook, Illinois 60062
?
mi
from
Northbrook, IL
Click here to add this to my saved trials
Oceanside, California 92056
?
mi
from
Oceanside, CA
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials